

VOLUME 12 | NUMBER 1 | JANUARY 2010

CURRENT ONCOLOGY REPORTS

EDITOR-IN-CHIEF Maurie Markman
ASSOCIATE EDITOR Herbert M. Pinedo

Breast Cancer

Section Editor ■ Kevin R. Fox

Neuro-oncology

Section Editor ■ Mark R. Gilbert

Current Oncology Reports is indexed by MEDLINE



Current Medicine Group is part of
Springer Science+Business Media

ALSO AVAILABLE ONLINE
www.springerlink.com



CURRENT ONCOLOGY REPORTS

EDITOR-IN-CHIEF Maurie Markman

2010


FEATURED SECTIONS

AVAILABLE ONLINE AND IN FULL COLOR

- Six bimonthly issues
- 80% clinical / 20% basic science content
- 60-70 articles per year
- Annotated references
- Clinical trial reports

Table 2. Conventional and emerging treatments

Treatment	Findings/notes
Cell agents	
SR vs IR oral morphine	In randomized, controlled trials, SR morphine for EOP was 4 weeks and IR morphine was 12 weeks.
Efficacy of morphine	This is uncontrolled, open-label study with 127 patients.
Randomized, placebo-controlled	This uncontrolled, open-label study with 127 patients.
ER hydrocodone/morphine	This uncontrolled, open-label study with 127 patients.
Oral methadone	In this uncontrolled, open-label study with 127 patients.
TK agents	
TK therapy	These open-label studies are needed to clarify the role of TK therapy.
TK hydrocodone/morphine	In a randomized, controlled trial, TK hydrocodone/morphine was superior to ER morphine in patients with EOP.
IV agents	
IV morphine	In two open-label studies, IV morphine was superior to ER morphine in patients with EOP.
IV hydromorphone	In this randomized, controlled trial, IV hydromorphone was superior to ER morphine in patients with EOP.
SC agents	
SC hydrocodone/morphine	In a randomized, controlled trial, SC hydrocodone/morphine was superior to ER morphine in patients with EOP.
SC morphine, SC hydromorphone, or SC hydromorphone vs SC morphine	In two small pilot studies, SC morphine, SC hydromorphone, or SC hydromorphone vs SC morphine was superior to ER morphine in patients with EOP.



VOLUME 12 | NUMBER 1 | JANUARY 2010

- **Breast Cancer**
- **Neuro-oncology**

VOLUME 12 | NUMBER 2 | MARCH 2010

- **Evolving Therapies**
- **Head and Neck Cancers**

VOLUME 12 | NUMBER 3 | MAY 2010

- **Gastrointestinal Cancers**
- **Genitourinary Cancers**

VOLUME 12 | NUMBER 4 | JULY 2010

- **Lung Cancer**
- **Palliative Medicine**

VOLUME 12 | NUMBER 5 | SEPTEMBER 2010

- **Leukemia**
- **Lymphomas**

VOLUME 12 | NUMBER 6 | NOVEMBER 2010

- **Pediatric Oncology**
- **Gynecologic Cancers**



Current Medicine Group is part of
Springer Science+Business Media